What Is Metabolic Health, and Where Do NAD+ and GLP-1s Fit In?

Key Takeaways

• Metabolic health reflects how efficiently your body processes and uses energy—measured through markers like blood glucose, triglycerides, blood pressure, waist circumference, and insulin sensitivity.
• NAD+ supports cellular energy production, mitochondrial function, and sirtuin activity, which is why it is relevant to metabolic health at the cellular level.
• GLP-1 receptor agonists are pharmaceutical drugs that work differently: they mainly affect appetite, satiety, gastric emptying, insulin secretion, and glucose regulation.
• NAD+ precursors and GLP-1 therapies are not interchangeable, and there is currently no human evidence that combining them improves outcomes.
• For now, the most evidence-based ways to support lean mass and metabolic health still include adequate protein, resistance training, sleep, and overall nutrition.

Metabolic health is emerging as a central theme in both consumer wellness and longevity conversations, shifting from a niche scientific topic to something people now regularly discuss alongside diet, exercise, and sleep. At the same time, glucagon-like peptide-1 (GLP-1)-based medications such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have seen a meteoric rise in use, becoming household names within just a few years.¹ As a result, “GLP-1s” are now the most visible entry point for modifying metabolic health, largely through their effects on appetite, insulin secretion, and weight loss. 

GLP-1 therapies may be the first direct intervention into these metabolic pathways for some people, even when the initial goal is framed as weight loss rather than long-term metabolic resilience. In parallel, a more cellular, mechanistic conversation has grown around nicotinamide adenine dinucleotide (NAD+) and its related precursor compounds, focusing on their roles in mitochondrial energy production and signaling pathways implicated in aging and metabolic disease. This has led to an increased interest in NAD+ precursors and peptide-based therapies among people who want to move beyond just weight loss alone toward supporting underlying metabolic function. 

Now, many are wondering: if GLP-1s can address the hormonal and appetite-related aspects of metabolism, can NAD+ and its precursors add complementary support at the cellular level? This article will explore that question by defining metabolic health, outlining where NAD+ fits into the equation at the cellular level, and clarifying how these processes relate to—rather than substitute for—GLP-1 therapies. 

What Is Metabolic Health? Key Indicators and Why It Matters

Metabolic health is how well your body processes and uses energy—everything from candy and kale to spinach and steak—and keeps key markers like blood sugar and triglycerides in a healthy range over time.² How well your body handles glucose and fats matters because poor metabolic health is strongly linked to a higher risk of type 2 diabetes, cardiovascular disease, fatty liver disease, and earlier mortality.³ In contrast, a healthier metabolism supports more stable energy, mood, and overall health over the lifespan.⁴

Specifically, metabolism is the collection of chemical reactions that turn food into usable energy and building blocks for your cells—for example, proteins get broken down into amino acids, while carbohydrates are broken down into glucose. Every time you eat, your body has to decide how much of that incoming fuel to burn right away, how much to store for later, and how to keep blood sugar and lipids within a safe range via hormones like insulin and glucagon.⁵ When this system works well, blood glucose rises and falls in a predictable, not erratic, pattern, and you can access energy steadily throughout the day. Excess calories are stored and released in a balanced way, rather than being locked into chronic fat gain.

In research and clinical practice, metabolic health is often defined using a handful of measurable indicators that assess how well your body’s energy systems are working. These markers include fasting blood glucose in the normal range (generally below 100 mg/dL), a waist circumference that does not indicate excess visceral fat around the organs, blood pressure below 120/80 mmHg without medication, and a healthy lipid profile characterized by triglycerides below 150 mg/dL, adequate HDL cholesterol, and well-managed LDL cholesterol (generally below 100 mg/dL). When these markers are all within their optimal ranges without the use of medication, an individual is generally considered metabolically healthy.⁶ However, these values serve as general guidelines rather than universal targets. The most appropriate ranges can vary based on factors such as age, medical history, and overall health, so they should always be interpreted in consultation with a healthcare professional.

Underlying these markers is insulin sensitivity—how well your cells respond to insulin’s signal to take up glucose from the bloodstream. When insulin sensitivity is high, blood sugar is easier to control, and blood pressure, lipids, and waist circumference often move in a similarly healthy direction. When insulin resistance develops—when your cells become less responsive to insulin—it can drive abnormalities in several of these indicators, and is considered an early step toward prediabetes, type 2 diabetes, and other metabolic diseases.⁷

Beyond these snapshot lab values, metabolic flexibility captures how well the body can switch between burning carbohydrates and fats. Someone with excellent metabolic flexibility can easily shift from “fed” to “fasted” states, handle a diet with mixed macronutrients, and transition from rest to exercise without dramatic swings in blood sugar, blood pressure, or repeated energy crashes.⁸ Diet, movement, sleep, stress, age, and underlying biology all influence this capacity. For example, ultra-processed foods and poor sleep tend to blunt metabolic flexibility, while nutrient-dense meals, regular exercise, and solid sleep hygiene support it.⁹ Ultimately, both metabolic health and metabolic flexibility depend on what is happening inside cells. That cellular layer is where NAD+ comes in.

What Is NAD+ and How Does It Support Metabolic Health?

NAD+ is a central metabolic cofactor that helps cells convert nutrients into usable energy, making it a vital component of metabolic health at the cellular level. Within mitochondria, NAD+ supports the reactions that help turn the food we eat into adenosine triphosphate (ATP), the energy currency cells use to function. NAD+ also acts as a required substrate for sirtuins, a family of enzymes that help regulate metabolism, mitochondrial function, and cellular stress responses.¹⁰ Sirtuins influence pathways involved in insulin sensitivity, lipid metabolism, mitochondrial biogenesis, and inflammation—and their activity depends on having enough NAD+ available.¹¹ As NAD+ levels decline with age or repeated exposure to metabolic stress, sirtuin activity is reduced as well,  which may contribute to the metabolic inefficiencies seen in aging and metabolic disease. 

Because directly supplementing with NAD+ has its challenges, most interventions focus on NAD+ precursors like nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), which the body can convert into NAD+. Clinical studies of these precursors have shown that raising NAD+ may impact several aspects of metabolic health. For example, NR has been reported to modestly improve body composition and sleeping metabolic rate,¹² and to show trends toward improved energy metabolism in some populations.¹³ Other work has found increased muscle mitochondrial biogenesis after NR supplementation, suggesting enhanced mitochondrial capacity in skeletal muscle.¹⁴ NMN has also been shown to improve muscle insulin sensitivity and insulin signaling in prediabetic women, supporting a link between NAD+ replenishment and glucose handling.¹⁵

Together, these findings suggest that supporting NAD+ levels with precursors may influence cellular energy production, mitochondrial function, and insulin sensitivity—all central to metabolic health. While some of these outcomes echo the metabolic improvements seen with GLP-1 therapies, NAD+ support works upstream, at the level of cellular energy metabolism, rather than through the appetite, hormone, and glucose signaling pathways targeted by GLP-1 drugs. 

What Are GLP-1s and How Do They Work?

GLP-1 receptor agonists (“GLP-1s”) are medications that mimic the gut hormone GLP-1, which is involved in glucose control and satiety, and they were first developed for type 2 diabetes before expanding into weight management.¹⁶ At a high level, GLP-1s work by increasing glucose-dependent insulin secretion, reducing glucagon, slowing gastric emptying, and helping people feel fuller sooner, which can lower caloric intake.¹⁶ 

This group now includes widely recognized drugs such as semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda), which have helped turn GLP-1s into the most visible part of a broader peptide therapy trend. Their rapid rise has also brought more attention to potential side effects, including gastrointestinal upset such as nausea and constipation,¹⁷ as well as evidence that weight loss may include some muscle mass along with fat.¹⁸ That raises a natural question for people already using a GLP-1: where does NAD+ fit in, and could supporting cellular energy metabolism offer complementary support for muscle mass during GLP-1-driven weight loss?

NAD+ and GLP-1s: How They Differ, and Whether They Work Together

GLP-1s and NAD+ precursors are not interchangeable: GLP-1s are pharmaceutical interventions that primarily target appetite, satiety, gastric emptying, and glucose regulation, while NAD+ precursors are aimed at supporting cellular energy metabolism more broadly. They are best thought of as different tools for different aspects of metabolic health, rather than competing solutions. That distinction matters because consumers may now be encountering both terms in the same wellness conversations—especially as peptide therapy and longevity-related products have moved into the mainstream. The emerging question is whether these tools complement each other rather than replace one another. 

The rationale is that NAD+ precursors have shown effects on muscle mitochondrial function and insulin sensitivity in human studies,¹⁹ which is why some people wonder whether NAD+ support could help address the loss of muscle mass that can accompany accelerated weight loss from GLP-1s. However, that idea remains untested in humans in the context of combined use—no clinical studies yet have directly examined whether NAD+ precursors can improve outcomes associated with GLP-1 therapy. 

For now, the best-supported strategies for preserving lean body mass during GLP-1 use are still adequate protein intake and resistance training. So while the NAD+ and GLP-1 question is biologically interesting and worth watching, it is still an active area of research rather than a settled recommendation.  

Putting It All Together: NAD+, GLP-1s, and the Bigger Picture of Metabolic Health

NAD+ and GLP-1s affect metabolism through different mechanisms. NAD+’s role in metabolism and its age-related decline is well documented, but whether raising NAD+ alongside GLP-1 therapy improves outcomes remains untested and unproven. For now, that means this idea is interesting but not established. 

In the bigger picture, metabolic health is not a single lever to pull or a single drug (or supplement) to take. It reflects the sum of how cells produce energy, how hormones regulate appetite and glucose, and how daily habits like sleep, movement, and nutrition support those processes. Understanding where NAD+ and GLP-1s fit is less about choosing one over the other and more about seeing the larger system they both influence.

References

1. Drucker, D. J. (2025). GLP-1-based therapies for diabetes, obesity and beyond. Nature Reviews Drug Discovery, 24(8), 631–650. https://doi.org/10.1038/s41573-025-01183-8
2. Leziak, A., Lipina, J., Reclik, M., & Kocelak, P. (2025). Dietary Modulation of Metabolic Health: From Bioactive Compounds to Personalized Nutrition. Metabolites, 15(9), 624. https://doi.org/10.3390/metabo15090624
3. Cho, L. W. (2011). Metabolic syndrome. Singapore Medical Journal, 52(11), 779–785.
4. Fardet, A., & Rock, E. (2016). The healthy core metabolism: A new paradigm for primary preventive nutrition. The Journal of Nutrition, Health and Aging, 20(3), 239–247. https://doi.org/10.1007/s12603-015-0560-6
5. Laurenti, M. C., Arora, P., Man, C. D., Andrews, J. C., Rizza, R. A., Matveyenko, A., Bailey, K. R., Cobelli, C., & Vella, A. (2022). The relationship between insulin and glucagon concentrations in non‐diabetic humans. Physiological Reports, 10(13), e15380. https://doi.org/10.14814/phy2.15380
6. Rhee, E.-J. (2018). Being Metabolically Healthy, the Most Responsible Factor for Vascular Health. Diabetes & Metabolism Journal, 42(1), 19–25. https://doi.org/10.4093/dmj.2018.42.1.19
7. Taylor, R. (2012). Insulin Resistance and Type 2 Diabetes. Diabetes, 61(4), 778–779. https://doi.org/10.2337/db12-0073
8. Goodpaster, B. H., & Sparks, L. M. (2017). Metabolic Flexibility in Health and Disease. Cell Metabolism, 25(5), 1027–1036. https://doi.org/10.1016/j.cmet.2017.04.015
9. Godsey, T. J., Eden, T., & Emerson, S. R. (2025). Ultra-Processed Foods and Metabolic Dysfunction: A Narrative Review of Dietary Processing, Behavioral Drivers and Chronic Disease Risk. Metabolites, 15(12), 784. https://doi.org/10.3390/metabo15120784
10. Imai, S., & Guarente, L. (2014). NAD+ and sirtuins in aging and disease. Trends in Cell Biology, 24(8), 464–471. https://doi.org/10.1016/j.tcb.2014.04.002
11. Zhou, S., Tang, X., & Chen, H.-Z. (2018). Sirtuins and Insulin Resistance. Frontiers in Endocrinology, 9, 748. https://doi.org/10.3389/fendo.2018.00748
12. Remie, C. M., Roumans, K. H., Moonen, M. P., Connell, N. J., Havekes, B., Mevenkamp, J., Lindeboom, L., Wit, V. H. de, Weijer, T. van de, Aarts, S. A., Lutgens, E., Schomakers, B. V., Elfrink, H. L., Zapata-Pérez, R., Houtkooper, R. H., Auwerx, J., Hoeks, J., Schrauwen-Hinderling, V. B., Phielix, E., & Schrauwen, P. (2020). Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans. The American Journal of Clinical Nutrition, 112(2), 413–426. https://doi.org/10.1093/ajcn/nqaa072
13. Ahmadi, A., Begue, G., Valencia, A. P., Norman, J. E., Lidgard, B., Bennett, B. J., Doren, M. P. V., Marcinek, D. J., Fan, S., Prince, D. K., Gamboa, J. L., Himmelfarb, J., Boer, I. H. de, Kestenbaum, B. R., & Roshanravan, B. (2023). Randomized crossover clinical trial of coenzyme Q10 and nicotinamide ribosome in chronic kidney disease. JCI Insight, 8(11), e167274. https://doi.org/10.1172/jci.insight.167274
14. Lapatto, H. A. K., Kuusela, M., Heikkinen, A., Muniandy, M., Kolk, B. W. van der, Gopalakrishnan, S., Pöllänen, N., Sandvik, M., Schmidt, M. S., Heinonen, S., Saari, S., Kuula, J., Hakkarainen, A., Tampio, J., Saarinen, T., Taskinen, M.-R., Lundbom, N., Groop, P.-H., Tiirola, M., … Pirinen, E. (2023). Nicotinamide riboside improves muscle mitochondrial biogenesis, satellite cell differentiation, and gut microbiota in a twin study. Science Advances, 9(2), eadd5163. https://doi.org/10.1126/sciadv.add5163
15. Yoshino, M., Yoshino, J., Kayser, B. D., Patti, G. J., Franczyk, M. P., Mills, K. F., Sindelar, M., Pietka, T., Patterson, B. W., Imai, S.-I., & Klein, S. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 372(6547), 1224–1229. https://doi.org/10.1126/science.abe9985
16. Müller, T. D., Finan, B., Bloom, S. R., D’Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., Holst, J. J., Langhans, W., Meier, J. J., Nauck, M. A., Perez-Tilve, D., Pocai, A., Reimann, F., Sandoval, D. A., Schwartz, T. W., … Tschöp, M. H. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72–130. https://doi.org/10.1016/j.molmet.2019.09.010
17. Kim, J. A., & Yoo, H. J. (2025). Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning. Diabetes & Metabolism Journal, 49(4), 525–541. https://doi.org/10.4093/dmj.2025.0242
18. Gatto, A., Liu, K., Milan, N., & Wong, S. (2025). The Effects of GLP-1 Agonists on Musculoskeletal Health and Orthopedic Care. Current Reviews in Musculoskeletal Medicine, 18(10), 469–480. https://doi.org/10.1007/s12178-025-09978-3
19. Lapatto, H. A. K., Kuusela, M., Heikkinen, A., Muniandy, M., Kolk, B. W. van der, Gopalakrishnan, S., Pöllänen, N., Sandvik, M., Schmidt, M. S., Heinonen, S., Saari, S., Kuula, J., Hakkarainen, A., Tampio, J., Saarinen, T., Taskinen, M.-R., Lundbom, N., Groop, P.-H., Tiirola, M., … Pirinen, E. (2023). Nicotinamide riboside improves muscle mitochondrial biogenesis, satellite cell differentiation, and gut microbiota in a twin study. Science Advances, 9(2), eadd5163. https://doi.org/10.1126/sciadv.add5163